We are live on ! Find out more
VanEck Associates

VanEck Associates Portfolio holdings

AUM $133B
1-Year Est. Return 72.99%
This Fund
S&P 500
This Quarter Est. Return
+0.13%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$19.8B
AUM Growth
+$155M
Cap. Flow
+$505M
Cap. Flow %
2.55%
Top 10 Hldgs %
28.01%
Holding
708
New
61
Increased
262
Reduced
353
Closed
27

Top Buys

Rank Stock Value
1
B
Barrick Mining
B
+$230M
2
PSX icon
Phillips 66
PSX
+$157M
3
CNH
CNH Industrial
CNH
+$139M
4
GG
Goldcorp Inc
GG
+$116M
5
CNX icon
CNX Resources
CNX
+$113M

Sector Composition

Rank Sector Weight
1 Materials 42.53%
2 Energy 27.86%
3 Healthcare 5.32%
4 Industrials 5.18%
5 Consumer Staples 3.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ASML icon
151
ASML
ASML
$626B
$15M 0.08%
159,969
+11,522
+8% +$1.07M
ALKS icon
152
Alkermes
ALKS
$8.22B
$15M 0.08%
+367,736
New +$13.6M
ARMH
153
DELISTED
ARM HOLDINGS PLC ADS
ARMH
$14.8M 0.08%
271,230
-2,744
-1% -$134K
SQM icon
154
Sociedad Química y Minera de Chile
SQM
$19.2B
$14.3M 0.07%
567,672
-29,056
-5% -$750K
MU icon
155
Micron Technology
MU
$930B
$14.2M 0.07%
653,382
-54,338
-8% -$1.06M
AMAT icon
156
Applied Materials
AMAT
$403B
$13.8M 0.07%
779,803
+47,214
+6% +$823K
TRX icon
157
TRX Gold Corp
TRX
$254M
$13.7M 0.07%
7,852,541
-555,921
-7% -$1.17M
CBST
158
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$13.7M 0.07%
199,141
+42,447
+27% +$2.75M
MRK icon
159
Merck
MRK
$322B
$13.6M 0.07%
285,644
+5,914
+2% +$270K
SNY icon
160
Sanofi
SNY
$103B
$13.5M 0.07%
252,513
+8,762
+4% +$452K
ADI icon
161
Analog Devices
ADI
$179B
$13.4M 0.07%
263,548
+29,581
+13% +$1.44M
PPP
162
DELISTED
Primero Mining Corp
PPP
$13.4M 0.07%
3,013,000
+1,234,000
+69% +$6.39M
BMY icon
163
Bristol-Myers Squibb
BMY
$133B
$13.3M 0.07%
249,922
-27,356
-10% -$1.39M
GSK icon
164
GSK
GSK
$104B
$13.1M 0.07%
196,905
+9,885
+5% +$641K
BRD
165
DELISTED
BRIGUS GOLD CORP COM STK
BRD
$13.1M 0.07%
16,794,928
-294,994
-2% -$195K
MDVN
166
DELISTED
MEDIVATION, INC.
MDVN
$12.9M 0.07%
405,780
+49,100
+14% +$1.48M
ABBV icon
167
AbbVie
ABBV
$443B
$12.7M 0.06%
240,337
-26,516
-10% -$1.3M
BHC icon
168
Bausch Health
BHC
$2.58B
$12.6M 0.06%
106,984
-692
-0.6% -$75.8K
IONS icon
169
Ionis Pharmaceuticals
IONS
$8.6B
$12.4M 0.06%
312,108
+38,695
+14% +$1.38M
AZN icon
170
AstraZeneca
AZN
$263B
$12M 0.06%
202,357
-11,374
-5% -$618K
GORO icon
171
Goldgroup Mining Inc.
GORO
$157M
$12M 0.06%
2,639,785
+145,318
+6% +$746K
ABT icon
172
Abbott
ABT
$183B
$11.9M 0.06%
311,445
+781
+0.3% +$28.8K
NVO
173
Novo Nordisk
NVO
$208B
$11.9M 0.06%
642,350
-5,870
-0.9% -$102K
JOY
174
DELISTED
Joy Global Inc
JOY
$11.9M 0.06%
202,641
-31,255
-13% -$1.72M
AGN
175
DELISTED
Allergan Inc
AGN
$11.8M 0.06%
106,425
-221,044
-68% -$21.1M

Similar funds

VanEck Associates's Q4 2013 Portfolio in Review

As of Q4 2013, VanEck Associates held 708 positions worth $19.8B, up 0.79% from $19.6B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

VanEck Associates's Q4 2013 filing shows 61 new, 262 increased, 353 reduced and 27 closed positions. Its largest new stake was CNH Industrial: 13,883,315 shares worth $137M. The largest sale was Pioneer Natural Resource Co., an estimated $131M.

By sector, the portfolio is most concentrated in Materials at 43% of assets, down from 45% a quarter earlier, followed by Energy and Healthcare.

  • VanEck Associates's largest Q4 2013 buy was CNH Industrial: 13,883,315 shares worth $137M.
  • VanEck Associates added most to Barrick Mining in Q4 2013, an estimated $230M increase.
  • VanEck Associates's biggest Q4 2013 reduction was Pioneer Natural Resource Co., cutting an estimated $131M.
  • VanEck Associates fully exited iShares S&P 500 Value ETF in Q4 2013, selling an estimated $27.2M.
  • VanEck Associates's ten largest holdings make up 28% of its $19.8B portfolio in Q4 2013.
  • VanEck Associates opened 61 new positions and closed 27 in Q4 2013.
  • VanEck Associates's portfolio value rose 0.79% quarter-over-quarter to $19.8B.

Based on VanEck Associates's 13F filing for Q4 2013, filed 12 Feb 2014.